December 2009 Volume 6 Number 12
Visit Nature Reviews Urology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=5&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Urology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=48&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=76&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
*********************************************************************
Nature Reviews Urology Impact Factor: 2.874*
(*Journal Citation Reports, Thomson, 2008)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Featured Collection: Spanning the scope of andrology
brought to you by Asian Journal of Andrology
In celebration of 10 years of publication, Asian Journal of Andrology is
proud to present Featured Collection: Spanning the scope of andrology. This
special offer highlights the Editors' selection of prominent reviews and
original research articles from AJA.
For your enjoyment, access to articles in Featured Collection: Spanning
the scope of andrology has been set FREE for a limited time.
http://links.ealert.nature.com/ctt?kn=6&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Prostate cancer: Active surveillance-more than 'wishful' waiting?
p629 | doi:10.1038/nrurol.2009.219
http://links.ealert.nature.com/ctt?kn=14&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Prostate cancer: Bio-barcode PSA assay-an early warning system for
biochemical recurrence?
p630 | doi:10.1038/nrurol.2009.220
http://links.ealert.nature.com/ctt?kn=28&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Urinary incontinence: Placement of artificial urinary sphincters: perineal
or penoscrotal?
p630 | doi:10.1038/nrurol.2009.223
http://links.ealert.nature.com/ctt?kn=31&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Xenografts for sacrocolpopexy
p631 | doi:10.1038/nrurol.2009.224
http://links.ealert.nature.com/ctt?kn=21&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Treating advanced TCCU
p632 | doi:10.1038/nrclinonc.2009.180
http://links.ealert.nature.com/ctt?kn=26&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Kidney cancer: Can renal mass characteristics predict PN outcomes?
p632 | doi:10.1038/nrurol.2009.226
http://links.ealert.nature.com/ctt?kn=45&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Bladder cancer: Robotic cystectomy noninferior to open surgery
p633 | doi:10.1038/nrurol.2009.225
http://links.ealert.nature.com/ctt?kn=39&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
IN BRIEF
Stones | Pediatrics | Quality of life | Ethics
p633 | doi:10.1038/nrurol.2009.227
http://links.ealert.nature.com/ctt?kn=53&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Prostate cancer: Adjuvant radiotherapy can increase the risk of pelvic
second primary malignancy
p634 | doi:10.1038/nrurol.2009.221
http://links.ealert.nature.com/ctt?kn=67&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Prostate cancer: MRI detects hidden aggressive anterior tumors
p634 | doi:10.1038/nrurol.2009.222
http://links.ealert.nature.com/ctt?kn=65&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Health policy: Health-care implications of resident duty-hour restrictions
Suzanne Biehn Stewart, Charles D. Scales Jr and Judd W. Moul
p635 | doi:10.1038/nrurol.2009.230
Since 2003, duty hours for US resident physicians have been restricted
to 80 h per week. For the first time, a study in a surgical population
now demonstrates a reduction in mortality and morbidity associated with
the working-hour reform.
http://links.ealert.nature.com/ctt?kn=71&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Health policy: The UK 'postcode lottery' in renal cell carcinoma
James Larkin and Martin Gore
p636 | doi:10.1038/nrurol.2009.228
In the UK, a patient's residential address can determine whether they have
access to certain treatments. An audit of the effect of this 'postcode
lottery' on the survival of patients with advanced renal cell carcinoma
suitable for treatment with sorafenib or sunitinib highlights the iniquities
that can plague such allocation systems.
http://links.ealert.nature.com/ctt?kn=69&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Kidney cancer: Developing objective criteria to characterize renal masses
Michael Staehler
p638 | doi:10.1038/nrurol.2009.232
The R.E.N.A.L. system for classifying tumors aims to predict the surgical
challenges of partial nephrectomy. However, the factors involved in surgical
planning are many and complex, and are not adequately addressed in this
simplified system. The inclusion of oncological features and a 'surgical
skills factor' might contribute to its widespread utility.
http://links.ealert.nature.com/ctt?kn=92&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Kidney cancer: The prognostic value of urinary collecting system invasion
Alison M. Lake and Sam S. Chang
p639 | doi:10.1038/nrurol.2009.231
Data from a retrospective multicenter study have revealed that the presence
of urinary collecting system invasion portends a worse outcome in patients
with organ-confined disease. Evidence that cancer has spread into the
collecting system, in the context of other adverse prognostic factors,
should prompt clinicians to instigate closer follow-up of patients after
nephrectomy.
http://links.ealert.nature.com/ctt?kn=72&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Genetics: Prostate cancer risk stratification by genotype and PSA
Jonathan L. Wright and Daniel W. Lin
p641 | doi:10.1038/nrurol.2009.229
The use of PSA testing as a screening tool for prostate cancer is limited
by its low specificity. New data offer insight into how genotypic information
might be incorporated into PSA screening approaches to enhance their accuracy.
http://links.ealert.nature.com/ctt?kn=80&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Prostate cancer: Androgen deprivation therapy and bone loss
Eitan Amir and Ian F. Tannock
p642 | doi:10.1038/nrurol.2009.218
Denosumab, an inhibitor of RANKL, improves bone mineral density and reduces
the incidence of fractures in men who receive androgen deprivation therapy
(ADT) for prostate cancer. At present, however, a lack of comparison with
potent bisphosphonates limits the assessment of its utility in the prevention
of ADT-induced bone loss.
http://links.ealert.nature.com/ctt?kn=83&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Saturation biopsies for prostate cancer: current uses and future prospects
Nicolas B. Delongchamps and Gabriel P. Haas
Published online: 10 November 2009
p645 | doi:10.1038/nrurol.2009.213
There is a trend towards increasing the number of cores sampled during
ultrasound-guided prostate biopsy in an attempt to increase the likelihood
of detecting malignancy. Here, the authors' analysis of current data
indicates that this 'saturation' approach is best used to improve
histological characterization of cancer, and for monitoring of men with
a rising PSA level despite previous negative biopsy.
Abstract: http://links.ealert.nature.com/ctt?kn=55&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=84&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Urologic laparoendoscopic single-site surgery
Evangelos Liatsikos, Panagiotis Kallidonis, Iason Kyriazis, Abdulrahman
Al-Aown and Jens-Uwe Stolzenburg
p654 | doi:10.1038/nrurol.2009.217
Laparoendoscopic single-site surgery (LESS) represents an exciting
development in the field of minimally invasive surgery. In this Review,
authors from Greece and Germany discuss the challenges facing LESS, highlight
the potential of new specialized technology in this arena, and provide an
overview of contemporary clinical experience with this approach in urologic
surgery.
Abstract: http://links.ealert.nature.com/ctt?kn=57&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=90&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Shock wave lithotripsy: advances in technology and technique
James E. Lingeman, James A. McAteer, Ehud Gnessin and Andrew P. Evan
p660 | doi:10.1038/nrurol.2009.216
Shock wave lithotripsy (SWL) represents the only noninvasive surgical
treatment for urinary tract stones. Drawing on their considerable experience,
Lingeman and colleagues outline the current utility and limitations of SWL,
and highlight the technological advances that hold promise for improving the
safety and efficacy of this treatment modality in the future.
Abstract: http://links.ealert.nature.com/ctt?kn=58&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=17&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Intravesical oxybutynin in the pediatric neurogenic bladder
John Lazarus
Published online: 10 November 2009
p671 | doi:10.1038/nrurol.2009.214
Topical treatment of neuropathic bladder has been suggested as a viable
alternative to oral anticholinergic therapy in children, offering greater
efficacy and reduced side effects. Lazarus reviews the current status of
intravesical oxybutynin use, warning that although it has proven effective
in some studies, there remains a low level of evidence.
Abstract: http://links.ealert.nature.com/ctt?kn=46&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=16&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
----------------------
CASE STUDIES
----------------------
Laparoscopic nephrolithotomy in a patient with crossed fused renal ectopia
Alireza Aminsharifi, Reza Niroomand, Mohsen Kroup and Mohammad Mehdi Hosseini
p675 | doi:10.1038/nrurol.2009.198
A 32-year-old man, with a left-to-right crossed fused kidney containing
a 25 mm stone, underwent laparoscopic nephrolithotomy for calculus removal.
The authors provide a comprehensive description of the procedure, focusing
on its role in patients with renal fusion anomalies where the stone burden
is too large for extracorporeal shock wave lithotripsy.
Abstract: http://links.ealert.nature.com/ctt?kn=47&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=7&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Treatment of a patient with post-TURP hemorrhage using bilateral SAPE
Lincoln Tan, Sudhakar K. Venkatesh, David Consigliere and Chin Tiong Heng
p680 | doi:10.1038/nrurol.2009.215
Although rare, life-threatening hemorrhage remains a challenging complication
of transurethral resection of the prostate (TURP). In this Case Study,
authors from Singapore present a 74-year-old man with benign prostatic
hyperplasia who experienced post-TURP hemorrhage, complicated by TURP
syndrome, which was ultimately successfully treated by bilateral selective
arterial prostatic embolization.
Abstract: http://links.ealert.nature.com/ctt?kn=49&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=23&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Visit the Nature Reviews Urology website:
- Advanced online publication
- Search across related content from nature.com
- Web feeds (RSS)
- Downloadable PowerPoint slides of figures and supplementary information
http://links.ealert.nature.com/ctt?kn=60&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=75&m=34460688&r=MTc2NDg0NjM5NAS2&b=2&j=NjE4NDM1NTES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
